Category: Business

Business News

AbbVie Invests $70 Million to Expand Biologics Manufacturing and R&D Hub in Massachusetts

AbbVie

AbbVie has broken ground on a $70 million expansion of its Bioresearch Center in Worcester, MA, a key part of its $10 billion U.S. investment plan. The project will add new manufacturing suites and labs to increase domestic production of complex biologic medicines for immunology and oncology, creating new jobs and bringing key manufacturing capabilities from Europe to the United States.

Business Healthcare & Pharmaceuticals News

Pfizer Acquires Metsera in $4.9 Billion Deal, Bolsters Obesity Drug Portfolio

pfizer news

Pfizer has announced a definitive agreement to acquire clinical-stage biopharmaceutical company Metsera in a deal valued at an initial $4.9 billion, with the potential for an additional $2.4 billion in milestone payments. The acquisition is a strategic move to re-enter the lucrative weight-loss drug market by adding Metsera’s next-generation obesity and cardiometabolic disease treatments, including promising oral and injectable therapies, to Pfizer’s pipeline.

Business News

Amgen to Bolster U.S. Innovation with Over $600 Million Investment in New California Research Center

amgen

Biotechnology giant Amgen is investing over $600 million to build a new research and development hub in Southern California. The cutting-edge facility will bring together top scientific minds to advance the creation of new medicines and is expected to generate hundreds of jobs, reinforcing the company’s commitment to U.S.-based innovation.

Business Healthcare & Pharmaceuticals News

Gilead Sciences Reports Strong Q2 2025 Results, Raises Full-Year Guidance

Gilead

Gilead Sciences reports a successful second quarter for 2025, with total revenue climbing to $7.1 billion, driven by a 7% increase in its HIV franchise sales. Diluted EPS rose to $1.56. Following these strong results, Gilead has raised its full-year 2025 guidance, now expecting product sales between $28.3 billion and $28.7 billion.

Business Healthcare & Pharmaceuticals News

Eli Lilly Reports Strong Q2 2025 Financial Results with 38% Revenue Growth

Eli Lilly and Company

Eli Lilly and Company reported strong second-quarter 2025 financial results, with worldwide revenue increasing 38% to $15.56 billion. This growth was driven by a 42% increase in volume, particularly from the company’s key products Zepbound and Mounjaro. Reported earnings per share (EPS) for the quarter were $6.29, a 92% increase compared to the same period in 2024. Following these results, Lilly has raised its full-year 2025 revenue guidance to a range of $60.0 billion to $62.0 billion.